Immuron Q1 FY26 YoY growth

Sales Performance - Global Q1 sales reached AUD$2.0 million, representing a 34% increase compared to the prior comparative period (pcp) [1] - Australia Q1 sales were AUD$1.6 million, up 52% on pcp [1] - USA Q1 sales increased to AUD$0.4 million, reflecting a 44% growth on pcp [1] - Canada Q1 sales were AUD$0.0 million, down 92% on pcp [1] Growth Drivers - Continued growth in Australia attributed to increased awareness from digital and social media marketing, same store growth, new store openings, and increased travel from South East Asia [3] - In the U.S., sales growth driven by marketing initiatives including improved online presence on Amazon, local social media pages, and increased paid and organic social media marketing [4] - In Canada, sales are expected to improve as consumer promotions are anticipated towards the end of the calendar year, with efforts to build brand awareness through educational programs and promotions [5] Product Information - Travelan® is an over-the-counter immune supplement designed to reduce the likelihood of travelers' diarrhea caused by pathogenic bacteria [7] - The product is available in Australia as a listed medicine, in Canada as a licensed natural health product, and in the U.S. as a dietary supplement [8]